Screener
Novavax NVAX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Novavax’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
FAQ
- What is Novavax's cash & equivalents?
- Novavax (NVAX) reported cash & equivalents of $191.46M in Q2 2026.
- How has Novavax's cash & equivalents changed year-over-year?
- Novavax's cash & equivalents decreased by 24.5% year-over-year, from $253.74M to $191.46M.
- What is the long-term trend for Novavax's cash & equivalents?
- Over 5 years (2020 to 2025), Novavax's cash & equivalents has grown at a -15.3% compound annual growth rate (CAGR), from $553.4M to $240.63M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Novavax's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude